Navigation Links
Bionovo Announces Third Quarter 2011 Highlights and Financial Results
Date:11/10/2011

EMERYVILLE, Calif., Nov. 10, 2011 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI) today announced third quarter highlights and financial results for the three months ended September 30, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20111110/SF04662LOGO)

"We initiated the first pivotal Phase 3 clinical trial and are actively recruiting patients," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "We are now concentrating on the timely execution of the study and we anticipate results in approximately 18 months."

Key Events and Milestones

  • The Company initiated the first of two pivotal Phase 3 studies for its drug Menerba (MF101) for the treatment of menopausal hot flashes. The trial will be conducted at 50 clinical sites in the U.S. The trial is a randomized, double blind, placebo controlled study in 1,200 menopausal women suffering from 50 or more moderate to severe hot flashes per week.
  • The Company successfully completed a 28-day tolerability trial of Menerba in women investigating higher doses. As expected, there were no safety concerns, no reports of serious adverse events, no changes to blood pressure, heart rate or lab values and no cases of abnormal uterine findings on endometrial biopsies.  A dosing strategy has been established for the Phase 3 study.
  • In addition, in this same study, the Company reported an observed robust clinical effect of Menerba to reduce hot flashes after just 4 weeks of treatment. After 4 weeks of treatment with Menerba at 10g/day, the reduction in moderate to severe hot flashes was 69% (with a p value of 0.003). In addition, there was a 68% reduction in the number of nighttime awakenings due to hot flashes (with a p value of 0.001). The Menerba 10g/day dose used in this study has twice the po
    '/>"/>

  • SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
    2. Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
    3. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
    4. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
    5. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
    6. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
    7. Bionovo to Announce First Quarter Financial Results on Wednesday, May 11, 2011
    8. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
    9. Bionovo Announces 2010 Highlights and Year-End Financial Results
    10. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    11. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
    (Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
    (Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
    Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
    (Date:7/25/2014)... 25, 2014 CMS recently has imposed ... for providing inadequate access to prescription drugs. Agency audits ... health and safety of beneficiaries in areas such as ... and CMS is taking quick and firm actions to ... Services webinar, “Avoiding Costly Part D Sanctions: Rx ...
    (Date:7/25/2014)... Recently, the largest herpes dating website ... that there had been a large increase in the number ... Living with a sexually transmitted disease can be difficult, but ... from all around the world who manage to go on ... many STDs including HSV, HPV, HIV, chlamydia, thrush, syphilis, hepatitis, ...
    (Date:7/25/2014)... July 25, 2014 At World T.E.A.M. ... July 19, 17 participating developmentally-disabled teens and young adults ... if off-road bicycling, canoeing and hiking can be challenging. ... at the scenic Chesapeake and Ohio Canal National ... athletes both disabled and able-bodied. Under slightly overcast skies ...
    (Date:7/24/2014)... U.S. Preventive Services Task Force recently recommended computerized ... risk for cancer, but a potential problem with ... results on the screening test, only to be ... expressed concern that this high false-positive rate will ... study of National Lung Screening Trial participant responses ...
    (Date:7/24/2014)... July 24, 2014 Ticket Down is ... Tickets in Denver at the Sports Authority Field on July ... World Football Challenge) has brought some of the best club teams ... the World Cup still being raved about weeks after its completion, ... to see some of the biggest stars in the world compete. ...
    Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:The Number of People Living With HSV and HPV Greatly Increased- Survey on PositiveSingles.com 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3
    ... finding, appearing online in the journal Circulation, is the first ... work was done in mice, researchers say it is likely ... progresses in humans. , Dr. Brian Annex, professor of ... study stemmed directly from his clinical experience. Over and ...
    ... Center will conduct a series of public town hall meetings to ... proposed large cohort study on the role of genes and environment ... effort to inform the National Institutes of Health and other federal ... study might go forward. , One way to study a ...
    ... SANTA CLARA, Calif., Feb. 22 Finesse Solutions, ... life sciences process,applications, announced the appointment of John ... Mr. O,Connell is a,seasoned executive with over 25 ... most recently at OSIsoft where he successfully initiated,partner ...
    ... /PRNewswire-FirstCall/ - In light of Neurochem,Inc.,s (NASDAQ: ... Company,announces the departure, effective February 21, 2008, of ... Orfanos, MBB. Ch, MBA, Executive Vice,President, Strategic Planning ... President, Business Development. The possibility of their,acting as ...
    ... Medical,Center has opened a new Sleep Diagnostic Center ... with sleep disorders. The new center provides,two specially ... leg syndrome, narcolepsy, snoring, sleepwalking, and,other sleep difficulties., ... suffer from sleep disorders,according to the American Academy ...
    ... DVD images create peaceful visual environment, ease anxiety of ... care facilities, WASHINGTON TOWNSHIP, N.J., Feb. 21 ... tension and anxiety too,often are the rule rather the ... relax ..., A new line of scenic, relaxation ...
    Cached Medicine News:Health News:Genetic mutation found in peripheral artery disease 2Health News:Genetic town halls to be held in 5 US cities 2Health News:Neurochem announces departure of two members of management team 2Health News:New Sleep Diagnostic Center Opens at Methodist Mansfield 2Health News:New Scenic Relaxation Videos Help Reduce Stress, Promote Sense of Calm and Tranquility 2
    ... Tests are qualitative enzyme immunoassays (EIA) for ... (IgG or IgM, respectively) in serum. Equivocal ... be supplemented with a standardized western blot ... to support a clinical diagnosis of B. ...
    ... Thyroid Autoimmunity Test is an enzyme immunoassay ... autoantibodies against human thyroglobulin and human thyroid ... blood and is used as an aid ... thyroid gland disorders are characterized by detection ...
    ... is dot-blot assay system combining microwell EIA ... purified antigen set at a clinically meaningful ... is detected using the same reagent system ... combines antigens detected in Auto 4 detecting ...
    ... The ImmunoDOT Autoimmunity Screening Panel 4 ... for screening and detection of autoantibodies ... (SS-A, SS-B, RNP/Sm, and Sm) in ... aid in the diagnosis of systemic ...
    Medicine Products: